Jorge Cortes
MD
Director, Georgia Cancer Center
👥Biography 个人简介
Jorge Cortes has contributed to the development of CPX-351, a liposomal formulation of cytarabine and daunorubicin, for secondary and therapy-related AML. His extensive research in leukemia spans CML, AML, and ALL and has led to multiple FDA approvals. He has been a principal investigator on dozens of pivotal leukemia trials and is recognized for his translational contributions to liposomal chemotherapy in AML.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jorge Cortes 的研究动态
Follow Jorge Cortes's research updates
留下邮箱，当我们发布与 Jorge Cortes（Augusta University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment